Amgen's KRAS-blocking cancer drug shows broader tumor-killing activity

Amgen's KRAS-blocking cancer drug shows broader tumor-killing activity

STAT Plus: Amgen’s KRAS-blocking cancer drug shows broader tumor-killing activity than previously reported

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

Scientists have long known that mutations in a protein called KRAS cause cancer, but discovering drugs capable of blocking KRAS has proven difficult.

READ MORE